Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

As Market Crashes, India’s Wockhardt Is Pushed To Consider Equity Dilution To Raise Funds To Repay Debts

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - A headlong fall in market valuation of large Indian drug makers over the last year is pushing their promoters to consider equity stake dilutions to repay debts or honor similar commitments. India's sixth-largest drug maker Wockhardt may see its promoter Habil Khorakiwala dilute 10 to 15 percent of his and his family's 74 percent equity in favor of private-equity players to raise about $150 million, PharmaAsia News has learned

You may also be interested in...



After Months Of Silence, Wockhardt Says It Has “Enough Business Bandwidth” To Ensure Payments Of FCCBs

MUMBAI - Drug major Wockhardt indicated that it has "enough bandwidth" in its business model to ensure that all its balance payments will be made in the stipulated time, in response to PharmAsia News queries on market speculation about its forthcoming payment of foreign currency convertible bonds of nearly $110 million. The bonds are scheduled to come up for redemption in September later this year

After Months Of Silence, Wockhardt Says It Has “Enough Business Bandwidth” To Ensure Payments Of FCCBs

MUMBAI - Drug major Wockhardt indicated that it has "enough bandwidth" in its business model to ensure that all its balance payments will be made in the stipulated time, in response to PharmAsia News queries on market speculation about its forthcoming payment of foreign currency convertible bonds of nearly $110 million. The bonds are scheduled to come up for redemption in September later this year

PharmAsia News Notable Notes: Will Rising Rupee Continue To Hold Back Retooled Indian Pharma Firms?

NEW DELHI - A confluence of new revenues from contract research and manufacturing services, in-license deals from multinational drug firms, vigorous efforts to discover new drugs, a slew of successful patent challenges and an upbeat outlook for generic drug demand, make leading Indian pharma companies attractive investments in a downbeat global economy, according to a 55-page report by IDFC-SSKI, the investment banking subsidiary of Mumbai-based Infrastructure Development Finance Company

UsernamePublicRestriction

Register

LL1134882

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel